

up of necessary inputs such as fuel availability, environmental clearance, clearance from civil aviation, water availability etc. It is not practical to indicate a specific timeframe for the approval of the schemes.

Exorbitant prices of drugs

1513. SHRI BHUBANESWAR KALITA: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that the consumer is paying twelve times more than the correct prices of medicines;

(b) whether it is also a fact that the drug companies are still charging exorbitant prices because of the stay orders granted by various High Courts;

(c) the names of the drug companies which obtained stay orders against the price fixation orders of his Ministry;

(d) the names of drugs and formulations alongwith prices being charged by drug companies and prices fixed by his Ministry; and

(e) since when each of these companies got stay orders?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI R. K. JAI-CHANDRA SINGH): (a) and (b) Some companies are charging their own prices due to stay orders granted by various High Courts.

(c) to (e) Information to the extent available is given in the attached Statement (*See below*). Rest of the details will be collected and laid on the Table of the Rajya Sabha.

Statement

Sl. No.	Name of the Company	Name of the Bulk Drug Formulations
1	2	3
I. Delhi High Court :		
1.	M/s. Glindia (formerly known as M/s. Glaxo Labs. I. Ltd.)	Betamethasone and its formulations.
II. Supreme Court of India :		
1.	M/s. Geoffery Manners	Benzathine Pencilline and its formulations
2.	M/s. Pfizer Ltd.	Oxytetracycline, PAS and its salts and formulations based thereon.
3.	M/s. Hoechst India Ltd.	Baralgan, Pyrolidine Methyl Tetracycline, Pheniframine, Glybenclamide Frusemide, and formulations.
4.	M/s. Parke Davis	Retention price of Chloramphenicol.
5.	M/s. Ethnor Ltd.	Tetramesol and its formulations.
6.	M/s. Anil Starch	Dextrose Anhydrons.
7.	M/s. Merck Sharp & Dohne	Dexamethasone & its formulations.
8.	M/s. Tamil Nadu Dhadha	Calcium Lactate & its formulations.
9.	M/s. Griffon Labs.	Procaine Pencillin V and formulations.

1

2

3

III. *Bombay High Court :*

- | | |
|-------------------------------|--|
| 1. M/s. Parke Davis | Multivitamin formulations and categorisation. |
| 2. M/s. Pfizer Ltd. | Protinex Formulations. |
| 3. M/s. Warner Hindustan Ltd. | Multivitamin formulations, vitamins and certain other formulations and categorisation. |
| 4. M/s. Fulford India Ltd. | Gentamycin formulations. |
| 5. M/s. Duphar Interfran Ltd. | Silver Sulphadiazine and its formulations. |
| 6. M/s. John Wyeth & Bros. | Formulations. |
| 7. M/s. Parke Davis | Ferradol formulations. |
| 8. M/s. Carter Wallace | Diovos formulations. |

IV. *Calcutta High Court :*

1, M/s. Reckitt Colman

Disprin formulations

Increase in the import of drugs

1514. SHRI BHUBANESWAR KALITA: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that measures announced under New Drug Policy are silent on the subject of drain on foreign exchange;

(b) whether it is also a fact that no action has been taken for reviewing the list of drugs allowed under OGL;

(c) whether it is also a fact that the import of drugs have gone up around 100 crores within a period of two years; and

(d) if so, what steps have been taken to ban the drugs for import for which technologies are available and investments have already been made by Drug Industry?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI R. K. JAI-CHANDRA SINGH): (a) No, Sir.

(b) No, Sir.

(c) Yes, Sir. The total import of bulk drugs and formulations into the country during the last two years, year-wise are given below:

	(Rs. in crores)
1984-85	215.62
1985-86	267.40

(d) It is the endeavour of Government to encourage domestic production of all the bulk drugs and intermediates to restrict imports and to achieve self-sufficiency. Following steps have been taken to augment indigenous production:

(i) A number of bulk drugs have been identified where the manufacturers are allowed minimum economic capacity for setting up their projects.

(ii) In 1985, 94 bulk drugs and intermediates were delicensed for production in the country.

(iii) Registration with the OGTD are freely allowed to companies other than FERA and MRTP companies.